Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17067941 | 1.00 | NR1H3 (0.39) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL18500417 | 0.87 | SETD7 (0.39) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL21280228 | 0.87 | SETD7 (0.39) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL18500416 | 0.87 | SETD7 (0.39) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL12349924 | 0.85 | HRH3 (0.43) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL15333158 | 0.85 | HRH3 (0.43) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL15332364 | 0.85 | HRH3 (0.43) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL18781018 | 0.83 | SETD7 (0.40) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL25785236 | 0.83 | SETD7 (0.40) | NR1H3NR1H2SETD7GPR119MAP4K4 | |
| SCHEMBL25873048 | 0.82 | CTSK (0.41) | NR1H3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |